BiotechTube
uBriGene

uBriGene

Fremont, United States· Est.
ubrigene.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

uBriGene is a privately held, revenue-generating CDMO/CRO that has established itself as a key enabler in the rapidly growing cell and gene therapy sector. The company leverages six Centers of Excellence and has a track record of over 150 GMP batches and support for 20+ IND filings with major regulatory agencies. Its business model is built on providing end-to-end technical and manufacturing services, as well as selling proprietary research products, to biopharma clients developing advanced therapies. With facilities in the US and Asia, uBriGene is positioned to serve a global client base seeking to accelerate ATMP development from concept to clinic.

Genetics & GenomicsDiagnostics

Technology Platform

Integrated CDMO/CRO platforms for viral vectors (AAV, LV), RNA-LNP (mRNA, circRNA, saRNA), cell therapy manufacturing (CAR-T, iPSC, MSC), plasmids, and analytical testing.

Opportunities

The company is leveraged to the massive growth in cell and gene therapy, where a shortage of specialized manufacturing capacity creates high demand for CDMO services.
Expansion of its RNA/LNP platform beyond mRNA into circRNA and saRNA positions it at the forefront of next-generation nucleic acid therapeutics.
Its geographic footprint in both North America and Asia provides a unique advantage in serving a global client base and tapping into different regional markets and cost structures.

Risk Factors

uBriGene faces intense competition from larger, established CDMOs and risks associated with reliance on client success.
Operational execution risk is high due to the complex nature of GMP manufacturing for advanced therapies, where any quality failure could significantly damage reputation.
The rapid evolution of technology platforms also poses a risk of disruption, requiring continuous and costly capital investment to stay relevant.

Competitive Landscape

uBriGene operates in a highly competitive and fragmented CDMO landscape. It competes with large, diversified players like Lonza, Catalent, and Thermo Fisher Scientific, as well as specialized pure-play CGT CDMOs such as Oxford Biomedica, Brammer Bio (part of Thermo Fisher), and Andelyn Biosciences. Its differentiation lies in its integrated service offering across multiple ATMP modalities, a specific focus on novel RNA formats, and its dual US-Asia operational base.

More companies in Cell & Gene Therapy →More companies in United States →